$IDXX
IDEXX Laboratories, Inc. · NasdaqGS · Healthcare
- Market cap
- 44.15B
- Volume
- 398.0K
- P/E
- 39.38
- Day range
- 558.29 – 569.55
- 52w range
- 500.61 – 769.98
- Analyst target
- 698.00
AI Summary
Generating a unique summary for IDXX…
AI-generated for information only — not investment advice.
Share this ticker
$IDXX -1.13% at 560.38 Terry Smith and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/IDXX
Company summary
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Institutional ownership
Institutions hold 96.60% · insiders 0.22% · 1,848 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.17M | $4.58B | 10.37% | 2026-06-30 |
| Vanguard Capital Management LLC | 5.15M | $2.89B | 6.54% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 3.90M | $2.18B | 4.95% | 2026-06-30 |
| State Street Corporation | 3.75M | $2.10B | 4.76% | 2026-06-30 |
| Invesco Ltd. | 3.61M | $2.02B | 4.58% | 2026-06-30 |
| Geode Capital Management, LLC | 2.56M | $1.44B | 3.25% | 2026-06-30 |
| BAMCO Inc. | 1.98M | $1.11B | 2.51% | 2026-06-30 |
| Morgan Stanley | 1.36M | $759.93M | 1.72% | 2026-06-30 |
| Bank Of New York Mellon Corporation | 1.19M | $668.73M | 1.51% | 2026-06-30 |
| Arrowstreet Capital, Limited Partnership | 1.07M | $597.97M | 1.35% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| KINGSLEY LAWRENCE D | Director | Sale at price 532.08 per share. | 2.2K | 2026-09-04 |
| KINGSLEY LAWRENCE D | Director | Conversion of Exercise of derivative security at price 114.17 per share. | 2.2K | 2026-09-04 |
| EMERSON ANDREW | Chief Financial Officer | Conversion of Exercise of derivative security at price 178.26 per share. | 265.00 | 2026-08-20 |
| HOOLEY JOSEPH L. | Director | Stock Award(Grant) at price 558.80 per share. | 49.00 | 2026-07-30 |
| FENNELL GEORGE | Officer | — | 639.00 | 2026-06-01 |
| PEACOCK KAREN | Director | — | 101.00 | 2026-05-07 |
| VANDEBROEK SOPHIE V | Director | — | 257.00 | 2026-05-07 |
| KINGSLEY LAWRENCE D | Director | — | 339.00 | 2026-05-07 |
| HOOLEY JOSEPH L. | Director | — | 158.00 | 2026-05-07 |
| JUNIUS DANIEL M | Director | — | 257.00 | 2026-05-07 |
| SZOSTAK MARGARET ANNE | Director | — | 257.00 | 2026-05-07 |
| HOOLEY JOSEPH L. | Director | Stock Award(Grant) at price 560.80 per share. | 43.00 | 2026-04-30 |
Analyst ratings
Consensus score 2.07 (1 = strong buy, 5 = sell) · mean target 698.00
- JP MorganOverweightmain2026-10-16
- KeybancSector Weightinit2026-10-12
- BarclaysOverweightmain2026-08-11
- UBSNeutralmain2026-08-05
- CitigroupNeutralmain2026-08-05
- UBSNeutralmain2026-07-27
- UBSNeutralmain2026-04-28
- CitigroupNeutralinit2026-04-15
- StifelBuymain2026-03-31
- Piper SandlerNeutralmain2026-02-09
Earnings
Next report: 2026-11-02
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 3.40 | 3.15 | 0.25 |
| 4Q2025 | 3.08 | 2.94 | 0.14 |
| 1Q2026 | 3.47 | 3.41 | 0.06 |
| 2Q2026 | 4.27 | 3.93 | 0.34 |
SEC filings
- 10-QPeriodic Financial Reports2026-08-04Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-06-01Open
- 8-KCorporate Changes & Voting Matters2026-05-15Open
- 10-QPeriodic Financial Reports2026-05-05Open
- ARSAnnual Report to Shareholders2026-03-27Open
- 8-KCorporate Changes & Voting Matters2026-03-26Open
- PRE 14AProxy Statements2026-03-13Open
- 10-KPeriodic Financial Reports2026-02-20Open
- 8-KCorporate Changes & Voting Matters2026-02-13Open
- 8-KCorporate Changes & Voting Matters2026-02-02Open
Latest IDXX news
- Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
Fri, 23 Oct 2026 11:19:00 +0000
- IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?
Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc.’s share was trading at $553.48 as of October 21st 2026. IDXX’s trailing and forward P/E were 36.65 and 31.45 respectively […]
Thu, 22 Oct 2026 20:18:21 +0000
- IDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued?
IDEXX Laboratories (IDXX) drew fresh attention after Jefferies reiterated its Buy rating while cutting two animal health peers on pricing concerns, and highlighted diagnostics as relatively better insulated within the broader veterinary and livestock market. Recent trading has shifted in IDEXX Laboratories' favor, with a 7 day share price return of 5.47% and a 30 day share price gain of 8.27%. However, the year to date share price return is down 16.73% and the 1 year total shareholder return...
Wed, 21 Oct 2026 05:18:33 +0000
- Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tue, 20 Oct 2026 15:10:03 +0000
- Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mon, 19 Oct 2026 15:00:03 +0000
- IDEXX Laboratories’ Q3 2026 Earnings: What to Expect
IDEXX Laboratories is set to report its Q3 results next month, with analysts expecting single-digit year-over-year EPS growth.
Thu, 15 Oct 2026 12:51:57 +0000
- IDEXX Laboratories to Release 2026 Third Quarter Financial Results
WESTBROOK, Maine, October 01, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Thu, 01 Oct 2026 15:30:00 +0000
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX). Financial terms were not disclosed.
Wed, 30 Sep 2026 13:00:00 +0000